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The development of tissue engineering and regeneration constitutes a new platform for translational medical research. Effective
therapies for bone engineering typically employ the coordinated manipulation of cells, biologically active signaling molecules, and
biomimetic, biodegradable scaffolds. Bone tissue engineering has become increasingly dependent on the merging of innovations
from each of these fields, as they continue to evolve independently. This foreword will highlight some of the most recent advances
in bone tissue engineering and regeneration, emphasizing the interconnected fields of stem cell biology, cell signaling biology, and
biomaterial research. These include, for example, novel methods for mesenchymal stem cell purification, new methods of Wnt
signaling pathway manipulation, and cutting edge computer assisted nanoscale design of bone scaffold materials. In the following
special issue, we sought to incorporate these diverse areas of emphasis in order to reflect current trends in the field.
1. Introduction
The development of tissue engineering and regeneration
constitutes a new platform for translational medical research.
Effective therapies for bone engineering typically employ the
coordinated manipulation of cells, biologically active sig-
naling molecules, and biomimetic, biodegradable scaffolds.
Bone tissue engineering has become increasingly dependent
on merging innovations from each field, as they continue
to evolve independently. Given the complexity and diverse
nature of these research areas—from osteoprogenitor cell
biology to biomaterials—a summary that fully encompasses
the advances in bone tissue engineering is not possible.
Instead, this foreword will examine some of the most
recent advances in bone tissue engineering and regeneration,
emphasizing the interconnected fields of cell biology, signal-
ing biology, and biomaterial research.
2. Purified, Autologous Stem Cells
Tissue engineering efforts using autologous adult mesenchy-
mal stem cell (MSC) sources such as cryopreserved umbilical
cord blood, bone marrow, and adipose tissue have shown
considerable ability to regenerate bone tissue. However,
currently used sources of MSC populations require cultural
expansion or selection by plastic adherence before they are
effective or available for regenerative therapies. Phenotypic
changes resulting from exposure to in vitro conditions are
not well understood, and such changes can lead to nega-
tive therapeutic consequences such as reduced proliferation
rate and significant morphological changes [1]. Notably, the
former has been correlated with reduced bone formation
in cultured human bone marrow MSC (bmMSC), using
an ectopic mouse model [2]. Similarly, cord blood MSC
require expansion, while plastic adherence is used to isolate
multipotent MSC from adipose, comprising a portion of
adipose-derived stromal cells (ASC). Despite the relatively
high stem cell frequency in adipose, the heterogeneity of
the uncultured stromal vascular fraction (SVF) restricts its
effectiveness as a freshly isolated MSC source. Overall, even
MSC freshly isolated or at early passages are a heterogeneous
group of cells [3, 4].
Thus, cutting edge efforts have attempted to purify MSC
population, most often using fluorescence activated cell sort-
ing (FACS) by differential expression of cell surface markers.
Choosing markers that distinguish MSC for multipotency
and regenerative properties is an area of avid and ongoing
research. One step forward is the identification of a superior
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subset of adipose-derived stromal cells for bone regeneration.
Levi et al. reported a subset of ASC with low expression
of the MSC marker CD105 (Endoglin) [5] as an enriched
osteoprogenitor cell population with the downregulation of
TGF-𝛽1 signaling. In a similar attempt to purify ASC pop-
ulations, Chung et al. selected for CD90 (Thy-1) expression
to obtain a purified ASC subset population with enhanced
osteogenic potential [6]. These studies highlight how even
a single cell surface marker may be used in order to purify
a more potent progenitor cell population for bone tissue
engineering. Similar approaches have used diverse surface
markers to enhance for a given attribute or phenotype of
MSC. These include, for example, selecting for CD34+ ASC
for higher cell proliferation [7, 8], CD34+ CD90+ ASC
for improved vasculogenesis [9], and CD105+ ASC for
heightened chondrogenic potential [10, 11].
In another, not wholly dissimilar, tactic-MSC purification
has been performed via the deduction of the perivascular
origin of MSC [12–18]. Having found that MSC reside
in a perivascular distribution, investigators have attempted
to purify MSC by FACS mediated isolation of cells with
perivascularmarkers from several organs.These cells, termed
perivascular stem cells (PSC), encompass both pericytes
(CD146+, CD34−, CD45−, and CD56−) and adventitial cells
(CD34+, CD31−, and CD146−) [12, 19]. As PSC are abundant
in adipose, a highly vascular tissue, their purification obviates
the need and complication of cultural expansion or in vitro
selection. Additionally, PSC have exhibited expression of
MSC markers and multilineage multipotency in vitro while
enhancing both bone formation and bone repair in vivo, as
compared to unsorted SVF in mouse models [19, 20]. Thus,
adipose-derived PSC are an abundantly available autologous
source of safe and effective MSC progenitors. A further
review of perivascular MSC isolation by flow cytometry
is available [14] and reviews of PSC and pericytes’ ability
to regenerate or naturally generate other tissues are also
available [21–23].
Unfortunately, the use of culture expansion and fluo-
rescently label antibodies for flow cytometry manipulates
the cells and introduces animal products, warranting the
need for clinical trials and complicating regulatory approval.
Thus, such methods for cell therapies require FDA regulation
as well as the expense of following Good Manufacturing
Practices for antibodies and biologics used. Although still in
its infancy, label-free sorting using microfluidic technologies
may provide an alternative route to purifying multipotent
cells from mature tissue for autologous cell therapies. For
example, adrenal cortical progenitor cells were enriched
for using label-free size-based inertial ordering, removing
their differentiated counterparts in a microfluidic chip [24].
As nuclear deformability has been studied extensively as
a marker of pluripotency [25], similar sterile fluid flow
devices have incorporated hydrodynamic stretching to con-
firm this characteristic in human and murine embryonic
stem cells and their differentiated counterparts [26, 27].Thus,
mechanophenotyping cells from tissues containing MSC
may elucidate biophysical criteria for isolating mesenchymal
cells enriched for multipotency and regenerative properties.
Subsequent purification of such tissue digests based on
size and deformability, whether by active or passive sorting
techniques, may remove debris and unwanted, terminally
differentiated cells while yielding these enriched subsets.
With such biophysical sorting methods in development, it is
possible that FDA licensure for minimal manipulation may
be more easily obtainable for bone therapies.
Despite the emergence of biomarker-free sorting meth-
ods, molecular criteria are the current gold standard for
stem cell purification. Since safe isolation of abundant and
osteocapable cell sources has been accomplished, current
efforts focus on identifying surface and intracellular markers
indicative of high osteogenic potential as well responsiveness
to osteoinductive signals. Nevertheless the purification of
MSC for those with enhanced osteogenic potential has been
attempted from diverse avenues by multiple investigative
groups-showing robust, promising results.
3. Manipulation of Signaling
Pathways and Differentiation
A commonly studied method of promoting osteogenic dif-
ferentiation is to manipulate signaling pathways important
in skeletal development, such as Wnt [28], Hedgehog [29–
31], BMP (Bone Morphogenic Protein) [32–34], and the
emerging anti-inflammatorymolecule NELL-1 [30, 35–37]. A
transition away from an interest in BMP2 may be expected
due to an increasing side effect profile including postoperative
inflammation [35, 38] and osteoclast activation [39–41]. The
FDA has reported on safety concerns concerning BMP2 use
[42, 43].
Of the above-mentioned signaling pathways, perhaps
none is more intensely studied than components of the
Wnt pathway for the treatment of osteoporotic bone loss.
Romosozumab, a neutralizing antibody against Sclerostin,
an inhibitor of Wnt coreceptor LRP (low density lipoprotein
receptor-related protein) has shown to mimic high bone
mass disease sclerosteosis, enhancing osteoblastic differenti-
ation and bone formation [44, 45]. Amgen Inc. is currently
conducting Phase III clinical trials using this antibody to
treat postmenopausal osteoporosis [46]. Romosozumab joins
Amgen’s anti-RANK antibody Denosumab as FDA approved
osteoporosis treatments, all of which could be pursued
for tissue engineering applications. Similarly, a neutralizing
antibody against Wnt inhibitor Dkk1 (Dickkopf1), which
is in Phase I/II clinical trials for multiple myeloma, has
been observed to have anabolic bone activity [47]. Recently,
tyrosine kinase inhibitor dasatinib, the FDA approved cancer
drug Sprycel, was shown to stimulate Wnt signaling and
inhibit PDGFR-𝛽 (platelet derived growth factor receptor-𝛽)
and c-Src phosphorylation, promoting osteoblast differenti-
ation and inducing an anabolic bone effect in vitro and in
vivo while inhibiting osteoclast formation in hematopoietic
progenitor cells in vitro [48]. Another interesting approach,
coating the surface of hydrophilic titanium scaffoldswithWnt
agonist lithium chloride, via GSK3 inhibition, was shown to
increase bone density, independent of the scaffold [49]. This
approach exemplifies coordinated delivery of developmental
signaling modulation and biomimetic materials.
BioMed Research International 3
Manipulating expression and differentiation at the
genetic level also allows for potentially more closely orches-
trated control of cellular and tissue phenotype. Micro-RNAs
(miRNAs), small noncoding RNA involved in transcriptional
regulation, have recently been targeted to enrich bone regen-
eration. Enhanced bone formation and vascularization
were observed upon delivery of miRNA 26a in both
subcutaneous and cranial repair mouse models [50].
Likewise, transfection of MSC with mimics and inhibitors
of miRNAs 148 and 489 increased in vitro osteogenesis,
evaluated by calcium deposition and gene expression [51].
Comprehensive reviews are available for miRNA in bone
development and regeneration [52–54]. Likewise, with the
development of safer, nonviral transfection agents, gene
therapy via BMPs [55] and other growth factors have been
used to supplement bone reconstruction. Moreover, non-
viral vectors embedded in biodegradable scaffolds, termed
gene-activated matrices, allows for gradual and sustained
delivery of a gene postoperatively [56]. Bone tissue engi-
neering and regenerative therapies rely on speeding tissue
differentiation and controlling morphology by targeting
miRNA, introducing genes and recombinant proteins and
modulating developmental signaling pathways.
4. Use of Biomaterials
Design of biocompatible scaffolds for bone tissue engi-
neering requires the balance of an osteoinductive cellular
microenvironment, diffusion of soluble factors, flexibility,
and mechanical loading appropriate for the anatomical site
[57, 58]. Although there are limits on vascularization and
innervation in whole organ reconstruction, recent advances
in 3D printing (3D-P) provide a diverse source of scaf-
folds for bone tissue engineering. Tamjid et al. controlled
properties, such as adherence, proliferation, and uniform
tissue growth rate, of MCT3T-E1 preosteoblasts within the
pores of indirectly 3D-printed polycaprolactone scaffolds
by mimicking extracellular matrix (ECM) architecture with
hydrophilic additives, including titania ceramic nanoparti-
cles and bioglass microparticles particles [59]. In a similar
attempt, porous alginate hydrogels amalgamated with gelatin
microspheres loaded with BMP-2 were constructed with 3D-
P and were used to gradually release BMP-2 to goat MSC
in vitro [60]. Another freeform fabrication technique, laser
microstereolithography (L-MSTL), fabricates 3D structures
by selectively curing photopolymer on a moving platform
layer by layer [61, 62]. In a recent study, L-MSTL was
used to embed BMP-2 within poly(DL-lactic-co-glycolic
acid) (PLGA) microspheres on a poly(propylene fumarate)
photopolymer, which enhanced MT3T-E1 cell differentia-
tion in vitro and outperformed both unloaded scaffolds
and scaffolds made by the particulate leaching/gas foam-
ing method in an rat cranial injury repair model [63].
Overall, computer assistant nanoscale design of biomimetic
ECM, while still being in relative infancy of preclinical
investigation, has potential to create a biomaterials fabri-
cation platform for improved bone tissue engineering and
regeneration.
Such meticulous design of tissue engineered constructs
is necessary to allow for selective diffusion of biological
molecules as well as migration and patterning of regenera-
tive cells. Unfortunately, accurate in vivo prediction of the
biological consequences caused by varying biophysical and
biochemical properties of biomaterials is often not available
with in vitro techniques. However, several 3D organ cul-
tures have emerged, modeling the mechanical and biological
microenvironment and interactions in prospective organs
and implanted devices [64, 65].
Miniaturized fluid flow devices containing these 3D
cultures, termed “organs-on-chips,” are the cutting edge
alternative to animal models, allowing for high throughput
examinations of a tissue or a tissue engineered construct.
A microfluidic bone model was recently shown to monitor
osteoblast behavior as well as formation of bone tissue and
bacterial biofilm within an ink-jet printed poly(D,L-lactic-
co-glycolic) acid construct containing biphasic calciumphos-
phate (BCP) and antibiotic nanoparticles [66]. While this
proof of concept investigates just one prospective implant,
several metrics were available to evaluate similar devices,
such as calcium deposition, 3D tissue development, biofilm
imaging, and osteoblast cell proliferation, migration, and
development [66]. This class of technology has been useful
in reproducing key physiological characteristics of an animal
model, using in vitro cultures to more accurately predict
in vivo consequences and success. In the design of novel
biomimetic implantablematerials, often laden with biologics,
the ability to study tissue biology at high throughput affords
the opportunity for accelerated progress in the field of bone
tissue engineering and regeneration.
5. Conclusions
Briefly, we have covered recent advances in cell signaling
biology, MSC isolation and purification, and biomaterials
relevant to bone tissue engineering and regeneration. In the
following special issue of BioMed Research International, we
sought to incorporate these diverse areas of emphasis in order
to reflect current trends in the field.
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